Good Therapeutics, Inc.

Good Therapeutics, Inc. is a biotechnology and pharmaceutical company founded in 2016 in the United States. The company's slogan "Systemic delivery, local activity" encapsulates its focus on developing protein-based drugs with regulated, context-dependent activity. Unlike conventional protease-activated therapeutics, Good Therapeutics' approach involves the development of drugs that can sense their local environment and transition from an inactive to an active form, with the mechanism being reversible. This innovative technology is based on allosteric control of protein activity, a form of regulation widely observed in nature but not yet applied to therapeutics. The company recently secured an $8.00M Series B investment on 30 December 2021 from a group of notable investors, including 3x5 Partners, RiverVest, Digitalis Ventures, and Roche Venture Fund. Good Therapeutics' unique approach and recent investment position it as an intriguing player in the biotechnology and pharmaceutical industries, with significant potential for growth and innovation.